文献速递自身炎症与 IgG4 相关病

全球秋水仙碱抵抗性家族性地中海热管理实践对比分析:一项CliPS网络分析

Comparative analysis of global practices in the management of colchicine-resistant familial Mediterranean fever: a CliPS network analysis.
PubMed 文献 · RMD Open · 2025-09-26

该研究通过CLiPS网络对46个国家223名专家进行问卷调查,旨在呈现秋水仙碱抵抗性家族性地中海热的定义流程及生物制剂使用指征。结果显示45.6%(73/160)的受访者以近6个月内3至4次发作为抵抗定义,95.7%(157/164)使用C反应蛋白作为急性期反应物,74%(n=165)认为并发症、发作严重度等补充因素影响抵抗定义。

要点

  • 45.6%(73/160)受访者以近6个月内3至4次发作定义秋水仙碱抵抗。
  • 95.7%(157/164)受访者使用C反应蛋白作为急性期反应物。
  • 74%(n=165)受访者认为并发症、发作严重度等补充因素影响抵抗定义。

核心结论

  • 研究呈现了描述医生对秋水仙碱抵抗性家族性地中海热管理策略总体态度及独特发现的新流程图,并揭示了受流行病学和社会经济因素影响的趋势变化。

研究设计与样本

  • 由JIR队列发起的eCOST网络在CLiPS倡议下开展的一项关于「单基因自身炎症性疾病生物制剂」的全球专家问卷调查,共纳入来自46个国家的223份应答。

主要发现

  • 45.6%(73/160)的受访者认为近6个月内3至4次发作是其秋水仙碱抵抗定义所必需的。
  • 最常用的急性期反应物为C反应蛋白(157/164,95.7%)。
  • 74%(n=165)的受访者认为包括家族性地中海热并发症、发作严重度、升高的活动度评分、患者报告结局和生活质量量表在内的补充因素影响其秋水仙碱抵抗定义。

关键数值与推荐

  • 秋水仙碱抵抗定义中,45.6%(73/160)受访者要求近6个月内3至4次发作。
  • 急性期反应物使用C反应蛋白的比例为95.7%(157/164)。
  • 74%(n=165)受访者将补充因素纳入秋水仙碱抵抗定义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although colchicine is the mainstay of familial Mediterranean fever (FMF) treatment, 5-10% of patients are considered to have colchicine resistance (CR). However, there is no globally agreed CR definition or indications for biological disease-modifying anti-rheumatic drugs (bDMARDs). METHODS: A survey on 'Biologics in Monogenic Autoinflammatory Diseases', part of the 'Clinical Practice Strategies' (CLiPS) initiative, was conducted by a JIR cohort-initiated eCOST network among expert participants worldwide. Our primary aim was to provide a flowchart reflecting the different CR definitions and present data regarding bDMARD indications. The secondary aim was to determine how specific biases influence clinical approaches. We analysed the CliPS according to the experience levels of physicians, country-specific FMF prevalence, countries' gross domestic product, bDMARD availability and reimbursement policies of the countries. RESULTS: A total of 223 responses from 46 countries were included in the study. Almost half of the respondents (73/160, 45.6%) indicated that three to four attacks within the preceding 6 months were necessary for their CR definition. The most frequently used acute-phase reactant was C-reactive protein (157/164, 95.7%). Almost three-fourths of the respondents (74%, n=165) considered that supplementary factors, including complications of FMF, attack severity, elevated activity scores, patient-reported outcome and quality of life scales, influenced their CR definition. CONCLUSION: We present a novel flowchart describing physicians' general attitudes and unique findings regarding management strategies for colchicine-resistant FMF and shifting trends influenced by epidemiological and socioeconomic factors.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Haslak F, Oner N, Elhani I, et al. Comparative analysis of global practices in the management of colchicine-resistant familial Mediterranean fever: a CliPS network analysis. RMD Open. 2025. PMID: 41005976. doi:10.1136/rmdopen-2025-006097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。